Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions

Cancer

Volumn 114, Issue 1, 2008, Pages 49-56

  Hanley, Krisztina Z ^a   Facik, Michael S ^a   Bourne, Patricia A ^a   Yang, Qi ^a   Spaulding, Betsy O ^b   Bonfiglio, Thomas A ^a   Xu, Haodong ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

KOC RNA binding protein; L523S; Malignant mesothelioma; Metastatic carcinoma; Reactive mesothelial cells; Serous effusions

Indexed keywords

ANTIBODY; CALRETININ;

ARTICLE; BENIGN TUMOR; CANCER RECURRENCE; CANCER SURGERY; EFFUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MESOTHELIUM CELL; METASTASIS; PERICARDIUM; PERITONEAL CAVITY; PERITONEAL FLUID; PLEURA; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SEROSA; STAINING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PERICARDIAL EFFUSION; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 39749126191     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23254     Document Type: Article

References (27)

1. Kho-Duffin J, Tao LC, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol. 1999;20:57-62.
2. Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol. 2005;32:137-144.
3. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol. 2001;116:253-262.
4. Abutaily AS, Collins JE, Roche WR. Cadherins, catenins and APC in pleural malignant mesothelioma. J Pathol. 2003;201:355-362.
5. King JE, Thatcher N, Pickering CA, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology. 2006;48:223-232.
6. Bedrossian CW. Diagnostic problems in serous effusions. Diagn Cytopathol. 1998;19:131-137.
7. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol. 2005;32:151-155.
8. Kato Y, Tsuta K, Seki K, et al. Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol. 2007;20:215-220.
9. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14:2729-2733.
10. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19:1262-1270.
11. Simon R, Bourne PA, Yang Q, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol. 2007;38:1178-1183.
12. Sojka KM, Spaulding BS, Nielsen GK, Dinnogen SA, Welcher R. Immunoreactivity of anti-L523S on normal and malignant lung pleural tissue biopsies. Mod Pathol. 2006;18(S1):288A.
13. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol. 2007;38:555-563.
14. Yaniv K, Yisraeli JK. The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene. 2002;287:49-54.
15. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29:188-195.
16. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7:556-564.
17. Istvanic S, Fanger GR, Fraire AE, et al. Spectrum of KOC (K homology domain containing protein over-expressed in cancer) immunostaining among carcinomas of different sites. Mod Pathol. 2005;18(S1):298A-299A.
18. Gress TM, Muller-Pillasch F, Geng M, et al. A pancreatic cancer-specific expression profile. Oncogene. 1996;13:1819-1830.
19. Mueller F, Bommer M, Lacher U, et al. KOC is a novel molecular indicator of malignancy. Br J Cancer. 2003;88:699-701.
20. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003;88:887-894.
21. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol. 2007;20:242-247.
22. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem. 2005;280:18517-18524.
23. O'Dell SD, Day IN. Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol. 1998;30:767-771.
24. Schmid C. Insulin-like growth factors. Cell Biol Int. 1995;19:445-457.
25. Reik W, Constancia M, Dean W, et al. Igf2 imprinting in development and disease. Int J Dev Biol. 2000;44:145-150.
26. Foulstone E, Prince S, Zaccheo O, et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol. 2005;205:145-153.
27. Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res. 2000;10(Suppl B):S21-24.